



MERCK

Merck & Co., Inc.
One Merck Dr.
Whitehouse Station, NJ 08889

MATERIAL SAFETY DATA SHEET

Merck Animal Health urges each user or recipient of this MSDS to read the entire data sheet to become aware of the hazards associated with this material.

SECTION 1. IDENTIFICATION OF SUBSTANCE AND CONTACT INFORMATION

MSDS NAME: Florfenicol (300 mg/mL)-Flunixin (16.5 mg/mL)-2-Pyrrolidone Injectable Solution

SYNONYM(S): RESFLOR (2-Pyrrolidone) Injectable Solution
RESFLOR Injectable Solution - Reformulation
RESFLOR (2-Pyrrolidone) Cattle Injectable
RESFLOR Gold

MSDS NUMBER: SP001649

EMERGENCY NUMBER(S): (908) 423-6000 (24/7/365) English Only
Emergencies - CHEMTREC:
(800) 424-9300 (Inside Continental USA)
(703) 527-3887 (Outside Continental USA)

MERCK MSDS HELPLINE: (800) 770-8878 (US and Canada)
(908) 473-3371 (Worldwide)
Monday to Friday, 9am to 5pm (US Eastern Time)

The brand-names or trademarks indicated by CAPITAL LETTERS in this [M]SDS are the property of, licensed to, promoted or distributed by Merck & Co., Inc., its subsidiaries or related companies.

SECTION 2. HAZARDS IDENTIFICATION

EMERGENCY OVERVIEW

Solution

Yellow-brown

Odor unknown

Toxic by inhalation.

May be harmful if swallowed.

Irritating to eyes.

May cause allergic reactions in susceptible individuals.

May cause effects to:

gastrointestinal tract

respiratory system

blood

liver

kidney

male reproductive system

fetus

May cause impaired fertility.

May cause developmental effects.

Toxic to aquatic organisms.

May cause long-term adverse effects in the aquatic environment.

POTENTIAL HEALTH EFFECTS:

The toxicological properties of the mixture(s) have not been fully characterized in humans or animals. However, there are data to describe the toxicological properties of the individual ingredients. The following summary is based upon available information about the individual ingredients of the mixture(s), or of the expected properties of the mixture(s).

Florfenicol is a broad spectrum antibiotic used in veterinary products. Florfenicol may cause allergic reactions in susceptible individuals. Based on animal studies, florfenicol may cause slight eye irritation, constipation, changes in blood cell counts, changes in stool, or liver effects. It may also cause developmental effects or effects to male reproductive organs.

Flunixin meglumine is a potent non-narcotic, non-steroidal agent with pain killing, anti-inflammatory, and fever-reducing activity. Based on animal studies, flunixin meglumine may cause severe eye irritation or irreversible ocular effects. It may also cause irritation of the skin, mucous membranes, respiratory tract, and gastrointestinal tract. Repeated dermal contact to high concentrations may cause severe skin irritation. Prolonged inhalation may produce serious lung effects. Repeated ingestion or inhalation of high doses may cause internal bleeding, predominantly of the gastrointestinal tract.

Glyceryl triacetate may cause slight to moderate eye irritation based on animal studies.

2-Pyrrolidone may cause fetal effects based on animal studies.

Malic acid is a relatively strong acid. It may cause severe eye irritation, and skin and mucous membrane irritation.

LISTED CARCINOGENS

No carcinogens or potential carcinogens listed by OSHA, IARC, NTP or ACGIH are present in concentrations >0.1% in this mixture.

SECTION 3. COMPOSITION AND INFORMATION ON INGREDIENTS

PRODUCT USE: Veterinary product

CHEMICAL FORMULA: Mixture.

The formulation for this product is proprietary information. Only hazardous ingredients in concentrations of 1% or greater and/or carcinogenic ingredients in concentrations of 0.1% or greater are listed in the Chemical Composition table. Active ingredients in any concentration are listed. For additional information about carcinogenic ingredients see Section 2.

CHEMICAL COMPOSITION

MSDS NAME: Florfenicol (300 mg/mL)-Flunixin (16.5 mg/mL)-2-Pyrrolidone Injectable Solution
Latest Revision Date: 20-Jan-2012

MSDS NUMBER: SP001649

INGREDIENT	CAS NUMBER	PERCENT
Florfenicol	73231-34-2	25
Glyceryl Triacetate	102-76-1	40-50
2-Pyrrolidone	616-45-5	20-30
Malic Acid	6915-15-7	<10
Flunixin Meglumine	42461-84-7	2.2

ADDITIONAL INFORMATION:

This MSDS is written to provide health and safety information for individuals who will be handling the final product formulation during research, manufacturing, and distribution. For health and safety information for individual ingredients used during manufacturing, refer to the appropriate MSDS for each ingredient. Refer to the package insert or product label for handling guidance for the consumer.

SECTION 4. FIRST AID MEASURES

INHALATION:

Remove to fresh air. Administer artificial respiration if breathing has ceased. IMMEDIATELY consult a physician.

SKIN CONTACT:

In case of skin contact, while wearing protective gloves, carefully remove any contaminated clothing, including shoes, and wash skin thoroughly with soap and water. If irritation or symptoms occur or persist, consult a physician.

EYE CONTACT:

In case of eye contact, immediately rinse eyes thoroughly with plenty of water. If wearing contact lenses, remove only after initial rinse, and continue rinsing eyes for at least 15 minutes. If irritation occurs or persists, consult a physician.

INGESTION:

Rinse mouth and drink a glass of water. Do not induce vomiting unless under the direction of a qualified medical professional or Poison Control Center. If symptoms persist, consult a physician.

NOTE TO PHYSICIAN:

This product contains florfenicol, a broad spectrum antibiotic which may cause allergic reactions in susceptible individuals. Flunixin meglumine is a potent Non-Steroidal Anti-inflammatory Drug (NSAID), and overexposure may cause gastrointestinal irritation and bleeding, kidney and central nervous system effects.

SECTION 5. FIRE FIGHTING MEASURES

FLAMMABILITY DATA:

Flash Point: Not determined (liquids) or not applicable (solids).

SPECIAL FIRE FIGHTING PROCEDURES:

Wear full protective clothing and self-contained breathing apparatus (SCBA).

SUITABLE EXTINGUISHING MEDIA:

Carbon dioxide (CO2), extinguishing powder or water spray.

See Section 9 for Physical and Chemical Properties.

SECTION 6. ACCIDENTAL RELEASE MEASURES

PERSONAL PRECAUTIONS:

Wear appropriate personal protective equipment as specified in Section 8. Keep personnel away from the clean-up area.

SPILL RESPONSE / CLEANUP:

All spills should be handled according to site requirements and based on precautions cited in the MSDS. In the case of liquids, use proper absorbent materials. For laboratories and small-scale operations, incidental spills within a hood or enclosure should be cleaned by using a HEPA filtered vacuum or wet cleaning methods as appropriate. For large dry or liquid spills or those spills outside enclosure or hood, appropriate emergency response personnel should be notified. In manufacturing and large-scale operations, HEPA vacuuming prior to wet mopping or cleaning is required.

ENVIRONMENTAL PRECAUTIONS:

This product is toxic to aquatic organisms. Do not allow product to reach ground water, water course, sewage or drainage systems.

See Sections 9 and 10 for additional physical, chemical, and hazard information.

SECTION 7. HANDLING AND STORAGE

HANDLING:

Keep containers adequately sealed during material transfer, transport, or when not in use. Wash face, hands, and any exposed skin after handling. Do not eat, drink, or smoke when using this substance or mixture.

Appropriate handling of this material is dependent on many factors, including physical form, duration and frequency of process or task, and effectiveness of engineering controls. Site-specific risk assessments should be conducted to determine the feasibility and the appropriateness of all exposure control measures. See Section 8 (Exposure Controls) for additional guidance.

STORAGE:

Store in a cool, dry, well ventilated area.

See Section 8 for exposure controls and additional safe handling information.

SECTION 8. EXPOSURE CONTROLS AND PERSONAL PROTECTION

The following guidance applies to the handling of the active ingredient(s) in this formulation.

OCCUPATIONAL EXPOSURE BAND (OEB):

OEB 3: 10-100 mcg/m³. Materials in an OEB 3 category are considered moderate health hazards. The OEB is a range of airborne concentrations expressed as an 8-hour Time Weighted Average (8-hr. TWA) and is intended to be used with Industrial Hygiene Risk Assessment to assist with industrial hygiene sampling and selection of proper controls for worker protection. Consult your site safety and industrial hygiene staff for guidance on handling and control strategies.

OCCUPATIONAL EXPOSURE GUIDELINE (OEG):

An Occupational Exposure Guideline (OEG) of 80 mcg/m³ (8-hr TWA) has been established for Florfenicol. Consult your site safety and industrial hygiene professional(s) for additional guidance.

An Occupational Exposure Guideline (OEG) of 18 mcg/m³ (8-hr TWA) has been established for flunixin. Consult your site safety and industrial hygiene professional(s) for additional guidance.

OEB/OEL NOTATION(S):

Florfenicol: This material has a notation of "A" for its ability to cause immediate allergic hypersensitivity reactions or anaphylaxis.

Flunixin Meglumine: This material has a notation of "C" for corrosivity.

EXPOSURE CONTROLS

The health hazard risks of handling this material are dependent on many factors, including physical form, duration and frequency of process or task, and effectiveness of engineering controls. Site-specific risk assessments should be conducted to determine the feasibility and the appropriateness of all exposure control measures. Exposure controls for normal operating or routine procedures follow a tiered strategy. Engineering controls are the preferred means of long-term or permanent exposure control. If engineering controls are not feasible, appropriate use of personal protective equipment (PPE) may be considered as alternative control measures. Exposure controls for non-routine operations must be evaluated and addressed as part of the site-specific risk assessment.

RECOMMENDED PERSONAL PROTECTIVE EQUIPMENT (PPE):

Respiratory Protection:	Respiratory protective equipment (RPE) may be required for certain laboratory and large-scale manufacturing tasks if potential airborne breathing zone concentrations of substances exceed the relevant exposure limit(s). Workplace risk assessment should be completed before specifying and implementing RPE usage. Potential exposure points and pathways, task duration and frequency, potential employee contact with the substance, and the ability of the substance to be rendered airborne during specific tasks should be evaluated. Initial and ongoing strategies of quantitative exposure measurement should be obtained as required by the workplace risk assessment. All RPE must conform to local and regional specifications for efficacy and performance. Consult your site or corporate health and safety professional for additional guidance.
Skin Protection:	Gloves that provide an appropriate barrier to the skin are recommended if there is potential for contact with this material. Consult your site safety staff for guidance.
Eye Protection:	Safety glasses with side shields. Use of goggles or full face protection may be required based on hazard, potential for contact, or level of exposure. Consult your site safety staff for guidance.
Body Protection:	<p>In small-scale or laboratory operations, lab coats or equivalent protection is required. Disposable Tyvek or other dust impermeable suit should be considered based on procedure or level of exposure. Use of additional PPE such as shoe coverings, gauntlets, hood, or head covering may be necessary. Consult your site safety staff for guidance.</p> <p>In large-scale or manufacturing operations, disposable Tyvek or other dust impermeable suit is recommended and based on level of exposure. Use of additional PPE such as shoe coverings, gauntlets, hood, or head covering may be necessary. Consult your site safety staff for guidance.</p>

EXPOSURE LIMIT VALUES

See Occupational Exposure Guideline (OEG) listed above.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

FORM: Solution
COLOR: Yellow-brown
ODOR: Odor unknown
SPECIFIC GRAVITY: 1.22
SOLUBILITY:
Water: Not determined

See Section 5 for flammability/explosivity information.

SECTION 10. STABILITY AND REACTIVITY

STABILITY/ REACTIVITY:
Stable under normal conditions.

INCOMPATIBLE MATERIALS / CONDITIONS TO AVOID:
None known.

HAZARDOUS DECOMPOSITION PRODUCTS / REACTIONS:
No dangerous decomposition is expected if used according to manufacturer's specifications.

SECTION 12. ECOLOGICAL INFORMATION

There are no data for the final product or its formulation(s). The information presented below pertains to the following ingredient(s).

ECOTOXICITY DATA

INGREDIENT ECOTOXICITY

Florfenicol: 96-hr LC50 (bluegill): >830 mg/L
Florfenicol: 96-hr LC50 (trout): >780 mg/L
Florfenicol: 48-hr EC50 (daphnid): >330 mg/L
Florfenicol: Algae maximum cell density: MIC = 1.5 mg/L
Florfenicol: Algae maximum growth rate: MIC >2.9 mg/L

Flunixin meglumine: 96-hr LC50 (trout): 9.2 mg/L
Flunixin meglumine: 96-hr LC50 (bluegill): 46 mg/L
Flunixin meglumine: 48-hr EC50 (Daphnia): 25 mg/L
Flunixin meglumine: 72 hr IC50 (Algae): 36-120 mg/L

ENVIRONMENTAL DATA

OTHER INGREDIENT ENVIRONMENTAL DATA:

Florfenicol: log Pow (log octanol/water partition coefficient): 2.36
Florfenicol: Solubility 1.32 mg/ml at pH 7
Florfenicol: Biodegradability: Not readily biodegradable but there is evidence of inherent biodegradability.

Flunixin Meglumine: log Pow (log octanol/water partition coefficient): 1.34

Glyceryl Triacetate: log Pow (log octanol/water partition coefficient): 0.25
Glyceryl triacetate is not expected to bioaccumulate or bioconcentrate in aquatic organisms. The estimated BCF is 1.3. It is expected to hydrolyse in soil and water to rapidly biodegradable products.

Malic Acid: log Pow (log octanol/water partition coefficient): -1.26

ENVIRONMENTAL FATE AND EFFECTS:

Photolytic half-life of Florfenicol in synthetic humic water (SHW) or pure water (PW) was 196 days in SHW and 171 days in PW.

SECTION 11. TOXICOLOGICAL INFORMATION

The toxicological properties of the mixture(s) have not been fully characterized in humans or animals. The information presented below pertains to the following individual ingredients, and not to the mixture(s).

MSDS NAME: Florfenicol (300 mg/mL)-Flunixin
(16.5 mg/mL)-2-Pyrrolidone Injectable Solution
Latest Revision Date: 20-Jan-2012

MSDS NUMBER: SP001649

ACUTE TOXICITY DATA

INHALATION:

Florfenicol: No mortality occurred in rats exposed to florfenicol for 4 hours at 0.28 mg/L (the maximum concentration tested). Clinical effects included dry rales, anogenital staining, secretory discharge, soft stool, and decreased body weights. These effects were seen immediately or up to one-week post exposure. Some effects did not resolve by study termination.

Flunixin Meglumine: Inhalation LC50 (4hr): <0.52 mg/L (rat)

Mortality occurred in all rats (10/10) between days 3 and 6 following a single 4-hour exposure to an average analytical concentration of 0.52 mg/L (maximum attainable exposure). Signs exhibited following exposure included lacrimation, nasal discharge, dried red material around facial area, and yellow anogenital staining. Significant weight loss was noted following exposure in all animals.

SKIN:

Florfenicol was not irritating to rabbit skin.

Flunixin meglumine: Slightly irritating

Flunixin meglumine produced mild, transient dermal irritation in rabbits. Dose-related skin irritation effects were observed in rabbits during a 21-day repeat skin application study (see below under Subchronic to Chronic Toxicity).

Glyceryl triacetate was not irritating when absorbed through the skin of guinea pigs.

2-Pyrrolidone was not irritating to the skin of rabbits.

Malic acid was moderately irritating to the skin of rabbits, and strongly irritating to the skin of guinea pigs.

EYE:

Florfenicol was slightly irritating to the eyes of rabbits.

Flunixin Meglumine: Severely irritating

All six animals exhibited severe conjunctival irritation including redness, swelling, discharge, and necrosis, as well as corneal opacity, ulceration and iridial damage. Severe ocular irritation was irreversible in most animals.

Rabbits treated with 0.1 ml of undiluted glyceryl triacetate exhibited slight to moderate irritation, but produced no effect when immediately rinsed for six minutes.

2-Pyrrolidone was not irritating to the eyes of rabbits.

Malic acid was severely irritating to the eyes of rabbits.

ORAL:

Florfenicol: Oral LD50: >2000 mg/kg (rat, mouse).

Dogs (one animal/sex) were administered successive oral doses of florfenicol that ranged from 160 to 1280 mg/kg. No clinical effects occurred at doses as high as 640 mg/kg. At 640 mg/kg, the only female died from inhalation of vomitus. Vomiting or soft stool occurred at 640 to 1280 mg/kg.

Flunixin Meglumine: Oral LD50: 53 to 157 mg/kg (rat), 176 to 249 mg/kg (male mouse, female estimated)

Flunixin (free acid): Oral LD50: 468.3 mg/kg (guinea pig)

Common effects observed in acute oral studies across species include gastrointestinal effects (perforation/ulceration and hemorrhage), hypoactivity, pallor, spleen enlargement, congestion of kidneys, lungs, or gastrointestinal tract, and respiratory distress. Necropsy of animals that died from flunixin meglumine revealed abnormalities of the brain, epididymides, abdominal cavity, thymus, liver, mesenteric lymph nodes, esophagus, mesentery, pancreas, and lungs. No signs of toxicity were observed following acute oral administration of 100 & 200 mg/kg to rhesus monkeys. However, 1 of 3 monkeys died following administration of 300 mg/kg. That monkey showed lethargy, prostration, and salivation prior to death, and signs of hyperemic mucosa in gastrointestinal tract and lungs at necropsy. Flunixin administered orally to mice at a dose of 300 mg/kg (100x the projected clinical dose) caused slight tremors and ataxia which resolved within 24 hours. Effects from acute oral and IV treatment of horses with 1.1 mg/kg flunixin were limited to sporadic incidence of fecal occult blood.

Glyceryl triacetate: Oral LD50: 3000-12800 mg/kg (rat); 1100-6100 mg/kg (mouse).

Symptoms observed during the determination of the oral LD50 in rats and mice were weakness and ataxia.

2-Pyrrolidone: Oral LD50: 328-6500 mg/kg (rat); 6500 mg/kg (guinea pig)

Malic Acid: Oral LD50: > 3200 mg/kg (rat); 1600-3200 mg/kg (mouse)

Signs of acute poisoning in rats and mice are weakness, retraction of the abdomen, respiratory distress, and cyanosis.

DERMAL AND RESPIRATORY SENSITIZATION:

Flunixin Meglumine was found not to be sensitizing in guinea pigs when tested by intradermal induction at 1% and topically at 100%.

Glyceryl triacetate was not a skin sensitizer in guinea pigs.

ADDITIONAL INFORMATION:

Florfenicol: Intaperitoneal LD50: 1913-2253 mg/kg (rat)

Clinical signs of toxicity noted in rats treated with 1000 to 2000 mg/kg florfenicol included hypoactivity, wet or stained urogenital hair, chromorrhinorrhea, or discolored stool. Abnormal pathological findings in rats included white, granular foci on surface of the liver or intestines, or pale or friable kidneys (high dose group).

REPEAT DOSE TOXICITY DATA**SUBCHRONIC / CHRONIC TOXICITY:**

Florfenicol was administered orally to dogs, rats, and mice at dosages as high as 100 to 400 mg/kg/day for up to 13 weeks. Effects including decreased body weight, changes in liver weight or liver enzyme levels, changes in testicular weight, testicular atrophy, decreased white blood cell counts, and decreased hemoglobin levels were observed at high dosages. Cellular changes in the liver or lymph nodes of rats and mice, and histopathologic changes in the brain and spinal cord of dogs were also noted at these high dosages. Although some effects were reversible after a 4-week withdrawal from treatment, testicular effects in rats persisted. Intramuscular injections of 45 mg/kg of florfenicol in swine produced diarrhea, injection site lesions, decreased body weight, decreased food and water consumption, changes in serum electrolytes and proteins, decreased red blood cell and white blood cell counts, decreased spleen weight, and decreased kidney weight.

In 52-week oral toxicity studies in dogs and rats, high dosages of florfenicol (12 and 48 mg/kg/day, respectively) increased liver weight and produced cellular changes in the gall bladder of dogs. In rats, florfenicol at the high dosage reduced body weight gain, reduced testicular weight, induced changes in hematologic and clinical chemistry parameters, and increased the incidence of testicular tubular atrophy. In two-year chronic studies in mice and rats, florfenicol caused similar effects as those observed in other long-term studies including reduced body weight gain, reduced red blood cell count, reduced hemoglobin levels, and testicular effects such as small testes, tubular atrophy and aspermatogenesis in both the high dosage rats (48 mg/kg/day) and mice (200 mg/kg/day).

Repeat oral dosing studies have been performed with flunixin across multiple species. The most common adverse effect seen in these studies is gastrointestinal irritation/ulceration and bleeding as indicated by blood in the stools. Other common adverse effects observed across species from oral, IV or IM routes of exposure include nephrotoxicity, emesis, anorexia, and bleeding. Blood cell count changes, blood coagulation effects, and immune organ effects were observed secondary to gastrointestinal erosion and bleeding. Liver, nervous system and behavioral effects were also noted in mice. In addition to ulceration and bleeding, significant mortality was observed in rats at 8 and 16 mg/kg dosed for six weeks. [6-week oral toxicity NOAEL: 2 mg/kg (rats); 90-day oral toxicity NOAEL: 5 mg/kg (monkeys), 3.0 mg/kg (rats); one year oral toxicity NOEL: 1 mg flunixin/kg (rats)]

In several 21-day repeat skin application studies in rabbits using up to 80 mg/kg flunixin meglumine or the free acid in spray or cream formulations, no conclusive treatment-related toxicity could be established. The incidence and severity of dermal irritation increased in a dose-related manner with severe irritation seen at 80 mg/kg/day.

Rats exposed to inhalation doses of glyceryl triacetate at 250 ppm for 13 weeks, and saturated vapors for 5 days, produced no symptoms or histopathological effects.

REPRODUCTIVE / DEVELOPMENTAL TOXICITY:

In a two-generation reproductive study, oral administration as high as 12 mg/kg/day of florfenicol reduced epididymal weights, decreased pup survival, and reduced lactation index in rats [NOAEL: 3 mg/kg/day].

There was no evidence of teratogenicity in rats administered florfenicol at dosages of 4, 12 or 40 mg/kg/day. Slight maternal toxicity, evidenced by decreased food and water consumption, was observed above 4 mg/kg/day. At 40 mg/kg/day, an increased incidence of delayed ossification and decreased fetal weight occurred. The NOAEL for maternal and fetal toxicity in rats was determined to be 4 mg florfenicol/kg/day.

Two teratogenicity studies were performed in mice. In the first study, the mice were administered florfenicol at dosages of 40, 120, or 400 mg/kg by gavage on days 6-15 of gestation. Florfenicol produced embryoletality at the 400 mg/kg/day dose level, which was evidenced by the high incidence of intrauterine deaths. Significant decreases in mean fetal body weight, soft tissue defects, and retarded skeletal ossification were also observed at 400 mg/kg/day. Skeletal ossification was less pronounced, in a dose-related fashion, at the lower doses tested (40 and 120 mg/kg/day). A developmental NOAEL could not be determined for these data [NOAEL for maternal: 120 mg/kg]. In the second teratogenicity study, florfenicol was retested at lower administered dosages of 1, 3, or 60 mg/kg/day. Maternal effects were limited to a slight increase in water consumption at the 60 mg/kg/day dose. There was no evidence of any adverse effects on the embryo/fetus at doses as high as 60 mg/kg/day in this study. However, based upon the retarded skeletal ossification effects observed in the first study at 40 mg/kg/day the NOAEL for the two studies combined was determined to be between 3 and 40 mg/kg/day.

Reproductive and teratology studies in rats, mice and rabbits were performed with flunixin. Although significant maternal toxicity, including mortality, was reported, these studies indicate that flunixin does not affect offspring development, male or female fertility, or mating behavior. A slight increase in the length of gestation and difficult labor with an increase in stillbirths were observed. No evidence of any drug-related teratogenic effects were observed. Maternal toxicity observed in these studies was consistent with those findings in acute and repeated dose oral toxicity studies with the addition of pale eyes, ears and extremities. [Reproductive or developmental NOELs ranged from 2-21 mg/kg in studies with multiple species. Maternal toxicity NOELs ranged from 3-9 mg/kg in these studies].

2-Pyrrolidone was embryotoxic but not teratogenic in mice exposed through oral and intraperitoneal routes of exposure. Maternal toxicity and malformations were observed in rats orally administered 1900 mg/kg/day. In a study conducted in rats, the inhalation of 150 ppm of 2-pyrrolidone on days 7 to 20 of gestation was associated with decreased pup weights and delays in developmental milestones.

MUTAGENICITY / GENOTOXICITY:

Florfenicol was negative in a bacterial mutagenicity study (Ames), a mammalian mutagenicity study (mouse lymphoma), a bone marrow micronucleus assay, an in vitro chromosomal aberration assay in CHO cells, a cytogenetics assay in bone marrow, and an unscheduled DNA synthesis assay in rat hepatocytes.

Flunixin meglumine was negative in the Ames and mouse micronucleus assays. It was positive in mouse lymphoma L5178Y cells, both in the absence and presence of S-9 metabolic activation and in the chromosomal aberration assay in CHO cells in vitro both in the absence and presence of S-9 metabolic activation. It has been reported to alter cellular DNA and caused primary DNA damage in E. coli. Flunixin free acid yielded the same results as flunixin meglumine. However, it was inconclusive in the bacterial repair assay in E.coli whereas flunixin meglumine was strongly positive. The meglumine moiety (N-methyl-D glucamine) was negative in all studies performed except the micronucleus study in which it was positive in one study and negative in a second.

2-Pyrrolidone was not mutagenic in a bacterial mutagenicity assay (Ames).

Malic acid was negative in bacterial mutagenicity studies (Ames), either in the absence or presence of metabolic activation. Malic acid was not clastogenic in Chinese hamster fibroblast cells.

CARCINOGENICITY:

Florfenicol was not carcinogenic in a 2-year study in rats administered dosages up to 48 mg/kg/day for 5 days a week or in mice at dosages up to 200 mg/kg/day for 5 days per week.

Flunixin meglumine had no carcinogenic effects or increase in tumor incidence relative to controls in either a 104-week study in rats administered 2, 4 and 8 mg flunixin meglumine/kg/day in the diet, or in mice administered 0.6, 2.0 and 6.0 mg flunixin meglumine/kg/day in the diet for 97 weeks. Significant toxicity observed in rats and mice included decreased body weights, increased mortality (high dose groups) and dose-related increases in gastrointestinal lesions in all treated groups. Compound-related lesions observed at necropsy included dose-related gastrointestinal ulcers, ulcer perforation with secondary peritonitis and adhesion formation, and large or edematous lymph nodes. Dose-related nonproliferative lesions were present in the gastrointestinal tract and mesenteric lymph node. Necrosis and ulceration of the mucosa, transmural necrosis, mucosal and mural inflammation, lymphoid hyperplasia, peritonitis and abscess formation were present. Inflammatory lesions and necrosis secondary to the peritonitis were present in other abdominal organs. Splenomegaly (enlarged spleens) were observed at necropsy in mice and were significant in the high dose group only. [Rat NOEL for tumor formation = 8 mg flunixin meglumine/kg/day and the LOEL = 2 mg flunixin meglumine/kg/day based on GI lesions. Mouse NOEL for tumor formation = 6.0 mg flunixin meglumine/kg/day; Toxicity NOEL = 0.6 mg flunixin meglumine/kg/day].

SECTION 13. DISPOSAL CONSIDERATIONS

MATERIAL WASTE:

Disposal must be in accordance with applicable federal, state/provincial, and/or local regulations. Incineration is the preferred method of disposal, when appropriate. Operations that involve the crushing or shredding of waste materials or returned goods must be handled to meet the recommended exposure limit(s).

PACKAGING AND CONTAINERS:

Disposal must be in accordance with applicable federal, state/provincial, and/or local regulations.

SPECIAL ENVIRONMENTAL HANDLING PROCEDURES:

This product contains materials that are harmful to the environment. Do not allow undiluted/unneutralized product to reach ground water, water course, sewage or drainage systems.

SECTION 14. TRANSPORT INFORMATION

This material is not subject to the transportation regulations of DOT, IATA, IMO, and the ADR.

SECTION 15. REGULATORY INFORMATION

TSCA LISTING

INGREDIENT	TSCA
Glyceryl Triacetate	X
2-Pyrrolidone	X
Malic Acid	X

Substances not included in the table above are TSCA exempt or not regulated under TSCA.

U.S. STATE REGULATIONS

INGREDIENT	California Proposition 65	CARTK	NJRTK	CTRTRK	MARTK
2-Pyrrolidone					X

INGREDIENT	PARTK	MNRTK	MIRTK	RIRTK
2-Pyrrolidone	X			

Fields in the above tables that do not contain data indicate that those materials have not been listed by local regulations.

X: Listed on applicable state hazardous substance or right-to-know lists.

SECTION 16. OTHER INFORMATION

Although reasonable care has been taken in the preparation of this document, we extend no warranties and make no representations as to the accuracy or completeness of the information contained therein, and assume no responsibility regarding the suitability of this information for the user's intended purposes or for the consequence of its use. Each individual should make a determination as to the suitability of the information for their particular purpose(s).

The brand-names or trademarks indicated by CAPITAL LETTERS in this [M]SDS are the property of, licensed to, promoted or distributed by Merck & Co., Inc., its subsidiaries or related companies.

DEPARTMENT ISSUING MSDS:

Global Safety & the Environment
Merck & Co., Inc.
One Merck Drive
Whitehouse Station, NJ 08889

MERCK MSDS HELPLINE:

(800) 770-8878 (US and Canada)
(908) 473-3371 (Worldwide)
Monday to Friday, 9am to 5pm (US Eastern Time)

MSDS CREATION DATE:

13-Apr-2006

SUPERSEDES DATE:

07-May-2010

SECTIONS CHANGED (US SUBFORMAT):
SIGNIFICANT CHANGES (US SUBFORMAT):

2, 11
OEB